Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abiomed (ABMD) and Seattle Genetics (SGEN).
Abiomed (ABMD)
Leerink Partners analyst Danielle Antalffy maintained a Hold rating on Abiomed today and set a price target of $280.00. The company’s shares closed last Monday at $278.24.
According to TipRanks.com, Antalffy is a 5-star analyst with an average return of 20.6% and a 65.9% success rate. Antalffy covers the Healthcare sector, focusing on stocks such as Axonics Modulation Technologies, Cardiovascular Systems, and Edwards Lifesciences.
Abiomed has an analyst consensus of Hold, with a price target consensus of $303.00.
See today’s analyst top recommended stocks >>
Seattle Genetics (SGEN)
Leerink Partners analyst Andrew Berens maintained a Buy rating on Seattle Genetics today and set a price target of $204.00. The company’s shares closed last Monday at $204.22, close to its 52-week high of $204.37.
According to TipRanks.com, Berens is a 5-star analyst with an average return of 16.8% and a 70.9% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Deciphera Pharmaceuticals, and Zentalis Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Seattle Genetics with a $186.08 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on SGEN:
